Title

close iconicon dots

General info

Why Type 1 Diabetes Screening Matters: What Every Parent with T1D Should Know

You've lived with Type 1 diabetes. You know the daily challenges, the middle-of-the-night blood sugar checks, and the constant vigilance. As a parent with T1D, one of your biggest concerns might be: "Will my child develop diabetes too?" The good news is that modern screening can help you stay ahead of the disease in ways that weren't possible when you were diagnosed.

Your Child's Risk: The Reality

Let's start with the facts. If you have Type 1 diabetes, your child's risk is 15 times higher than children in the general population. But here's what's important: higher risk doesn't mean certainty, and early detection can make all the difference.

According to the latest research, when children have multiple autoantibodies (the markers we screen for), 70% will develop Type 1 diabetes within 10 years, and the risk continues to increase over time. But catching this early—before symptoms appear—can dramatically change the outcome.

[ Image place ]

RISK OF DEVELOPING TYPE 1 DIABETES

General Population

0.4% lifetime risk

Children with 1 parent with T1D

15x higher risk (≈6%)

Children with 2+ autoantibodies

85-92% by age 15

Why Screen? Three Life-Changing Benefits

1. Preventing Diabetic Ketoacidosis (DKA)

This is perhaps the most critical reason to screen. DKA is a dangerous, sometimes life-threatening complication that occurs when Type 1 diabetes is diagnosed late. Here's the impact of screening:

  • Without screening: 30-40% of children are in DKA at diagnosis
  • With screening: Less than 5% experience DKA at diagnosis

When you know your child is at risk, you and your healthcare team can catch the transition to clinical diabetes before it becomes a medical emergency. You'll recognize the subtle changes in blood sugar before they spiral into a crisis.

2. Access to Disease-Modifying Therapies

In 2024, the FDA approved teplizumab, the first therapy that can delay the progression from Stage 2 to Stage 3 Type 1 diabetes. Clinical trials showed it delayed diagnosis by an average of 2-3 years.

But here's the catch: you can only access these therapies if you know your child is in the early stages. Screening makes this possible. As research continues, more interventions are in development—and early detection is the key to accessing them.

3. Emotional and Practical Preparation

Living with the uncertainty can be harder than knowing the truth. Screening provides clarity and allows you to:

  • Process emotions before a crisis hits
  • Educate your child gradually and age-appropriately
  • Make informed decisions about school, activities, and healthcare
  • Connect with support networks early
  • Plan financially and logistically for diabetes management

Understanding the Stages: The New Framework

The 2025-2026 ADA Standards of Care emphasize a new way of thinking about Type 1 diabetes—not as a sudden diagnosis, but as a progression through three stages:

[ Image place }

STAGE 1: Autoimmunity

STAGE 1

Autoimmunity

2+ autoantibodies present
Normal blood sugar
No symptoms
Can last months to years

STAGE 2

Dysglycemia

2+ autoantibodies present
Blood sugar abnormalities beginning
Still no symptoms
Can last months to years
ELIGIBLE FOR THERAPIES (like teplizumab)

STAGE 3

Clinical Diabetes

High blood sugar + symptoms
Requires insulin therapy
The "traditional" diagnosis

Why this matters: Screening identifies Stages 1 and 2—before symptoms appear. This is when intervention can make the biggest difference.

What the Latest Guidelines Say

The 2026 ADA Standards of Care specifically recommend:

"Antibody-based screening for presymptomatic type 1 diabetes in individuals with a family history of type 1 diabetes or otherwise known elevated genetic risk."

The 2024 Consensus Guidance goes further, providing detailed monitoring protocols for people identified through screening. These guidelines were developed by international experts specifically to support families like yours.

Who Should Be Screened?

According to current guidelines, screening is recommended for:

  • Children, adolescents, and adults with a first-degree relative with T1D (that's your children!)
  • Siblings of children already diagnosed
  • Individuals with known high-risk genetic markers (HLA genotypes)

The test is simple: a blood test that checks for four autoantibodies (GAD, IAA, IA-2, and ZnT8). Many screening programs, including Type 1 Diabetes TrialNet, offer free screening to eligible family members.

Addressing Your Concerns

"I don't want my child to live in fear."
Early knowledge doesn't mean constant worry. It means empowerment. Many families report that screening actually reduces anxiety because they have a clear plan and regular monitoring.

"What if the results show high risk but nothing can be done?"
Even without medication, there's much that can be done: education, careful monitoring, prevention of DKA, and emotional preparation. Plus, new therapies are emerging, and your child could be eligible.

"I feel guilty—did I cause this?"
Type 1 diabetes is not caused by anything you did or didn't do. It's an autoimmune condition with genetic factors. Screening is about prevention and preparation, not blame.

Taking Action

If you haven't already, talk to your child's pediatrician or endocrinologist about screening. Programs like Type 1 Diabetes TrialNet offer free antibody testing and monitoring for at-risk family members.

Remember: you can't change the genetics your child inherited, but you can change the trajectory of their experience with Type 1 diabetes. Screening transforms Type 1 diabetes from a sudden crisis into a manageable, anticipated condition—giving your family time, options, and hope.

References

  1. American Diabetes Association. (2026). 14. Children and Adolescents: Standards of Care in Diabetes—2026. Diabetes Care, 49(Supplement 1), S297-S316.
    https://diabetesjournals.org/care/article/49/Supplement_1/S297/163923/
  2. Beyond Type 1. (2025). 2025 ADA Standards of Care: New Recommendations for Early Detection of Type 1 Diabetes and CGM Access Expansion.
    https://beyondtype1.org/2025-ada-standards-of-care-what-they-say-about-autoantibody-screening-and-cgms-for-people-with-type-2/
  3. Wherrett, D. K., et al. (2024). Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care, 47(8), 1276-1298.
    https://diabetesjournals.org/care/article/47/8/1276/156880/
  4. Breakthrough T1D. (2024). Landmark International Consensus Guidance Provides a Framework for Clinicians to Monitor Those in Early-Stage Type 1 Diabetes.
    https://www.breakthrought1d.org/for-the-media/press-releases/landmark-international-consensus-guidance-provides-a-framework-for-clinicians-to-monitor-those-in-early-stage-type-1-diabetes/
  5. Type 1 Diabetes TrialNet. Pathway to Prevention: Risk Screening.
    https://www.trialnet.org/our-research/risk-screening

Related Articles

The latest news, technologies, and resources from our team.

How to Talk with Your Doctor About Your Child's Type 1 Diabetes Screening Results

Knowledge Base

Scientific materials

A concise overview of scientific research and findings related to type 1 diabetes.

Learn more

arrow

General info

General information about type 1 diabetes, its causes, and treatments.

Learn more

arrow

Video guides

Short video tutorials on testing and managing type 1 diabetes.

Learn more

arrow